Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Written by Emily J. Thompson, Senior Investment Analyst

VTGN+4.42%

Updated: Aug 07 2025

0mins

VTGN

$0.6627+Infinity%1D

Analyst Views on VTGN

Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 0.97 USD with a low forecast of 0.90 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

0 Buy

5 Hold

0 Sell

Hold

Current: 0.634

Low

0.90

Averages

0.97

High

1.00

Current: 0.634

Low

0.90

Averages

0.97

High

1.00

Lucid Capital

Buy

Neutral

downgrade

$19 -> $1

2025-12-17

Reason

Lucid Capital

Price Target

$19 -> $1

AI Analysis

2025-12-17

downgrade

Buy

Neutral

Reason

Lucid Capital downgraded Vistagen to Neutral from Buy with a price target of $1, down from $19. The company announced that its Phase 3 PALISADE-3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder failed to meet its primary endpoint, the analyst tells investors in a research note. The firm says that given the failure of the PALISADE-3 trial, there is "significant uncertainty" surrounding the likelihood of success for the ongoing PALISADE-4 study, which employs an identical design.

Stifel

Buy

Hold

downgrade

$12 -> $1

2025-12-17

Reason

Stifel

Price Target

$12 -> $1

2025-12-17

downgrade

Buy

Hold

Reason

Stifel downgraded Vistagen to Hold from Buy with a price target of $1, down from $12.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VTGN

Unlock Now

Stifel

Buy

Hold

downgrade

$12 -> $1

2025-12-17

Reason

Stifel

Price Target

$12 -> $1

2025-12-17

downgrade

Buy

Hold

Reason

As previously reported, Stifel downgraded Vistagen to Hold from Buy with a price target of $1, down from $12, after the company's PALISADE-3 study of fasedienol in social anxiety disorder did not meet its primary endpoint. The risk/reward is "highly upside-biased" as the PALISADE-4 study is ongoing and effective psychiatry drugs "do sometimes outright fail," so the probability of success for P4 is "not zero," but it is "very hard to have confidence," the analyst tells investors.

William Blair

Outperform -> Market Perform

downgrade

2025-12-17

Reason

William Blair

Price Target

2025-12-17

downgrade

Outperform -> Market Perform

Reason

As previously reported, William Blair downgraded Vistagen to Market Perform from Outperform after the "disappointing" PALISADE-3 social anxiety disorder study miss. With data from the PALISADE-4 study expected in the first half 2026, Vistagen has an additional shot on goal for a confirmatory study supportive of a fasedienol NDA filing, but with no separation from placebo on the primary SUDS endpoint and no secondary endpoints indicating a signal favoring treatment, the firm is now uncertain if fasedienol is an active agent for the acute treatment of SAD, the analyst tells investors.

About VTGN

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.